| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Obesity | 187 | 2025 | 2406 | 21.460 |
Why?
|
| Research Design | 42 | 2025 | 752 | 11.900 |
Why?
|
| Energy Intake | 52 | 2025 | 519 | 8.520 |
Why?
|
| Body Mass Index | 110 | 2025 | 1707 | 8.010 |
Why?
|
| Weight Loss | 52 | 2025 | 515 | 7.730 |
Why?
|
| Body Weight | 57 | 2024 | 1006 | 7.240 |
Why?
|
| Randomized Controlled Trials as Topic | 47 | 2025 | 1247 | 6.880 |
Why?
|
| Longevity | 31 | 2024 | 159 | 6.530 |
Why?
|
| Data Interpretation, Statistical | 28 | 2024 | 230 | 5.130 |
Why?
|
| Feeding Behavior | 24 | 2025 | 728 | 5.090 |
Why?
|
| Body Composition | 56 | 2025 | 559 | 4.750 |
Why?
|
| Eating | 24 | 2024 | 389 | 4.620 |
Why?
|
| Nutritional Sciences | 12 | 2021 | 76 | 4.520 |
Why?
|
| Pediatric Obesity | 16 | 2020 | 411 | 4.310 |
Why?
|
| Overweight | 18 | 2023 | 384 | 3.750 |
Why?
|
| Diet | 31 | 2025 | 1174 | 3.690 |
Why?
|
| Humans | 419 | 2025 | 132373 | 3.630 |
Why?
|
| Exercise | 19 | 2024 | 865 | 3.630 |
Why?
|
| Bias | 16 | 2025 | 144 | 3.560 |
Why?
|
| Weight Reduction Programs | 7 | 2025 | 60 | 3.410 |
Why?
|
| Energy Metabolism | 35 | 2024 | 804 | 3.280 |
Why?
|
| Models, Genetic | 29 | 2020 | 771 | 3.220 |
Why?
|
| Schools | 9 | 2023 | 238 | 2.990 |
Why?
|
| Models, Statistical | 31 | 2024 | 494 | 2.800 |
Why?
|
| Public Health | 8 | 2023 | 282 | 2.750 |
Why?
|
| Weight Gain | 23 | 2024 | 408 | 2.730 |
Why?
|
| Random Allocation | 14 | 2024 | 431 | 2.710 |
Why?
|
| Adipose Tissue | 31 | 2024 | 513 | 2.490 |
Why?
|
| Diet, Reducing | 12 | 2021 | 94 | 2.460 |
Why?
|
| Blood Glucose | 16 | 2024 | 1171 | 2.260 |
Why?
|
| Aging | 24 | 2024 | 1261 | 2.230 |
Why?
|
| Food | 10 | 2025 | 139 | 2.220 |
Why?
|
| Biomedical Research | 10 | 2020 | 553 | 2.170 |
Why?
|
| Social Class | 8 | 2019 | 207 | 2.120 |
Why?
|
| Dietary Supplements | 11 | 2024 | 482 | 2.110 |
Why?
|
| Statistics as Topic | 8 | 2018 | 254 | 2.080 |
Why?
|
| Breakfast | 4 | 2023 | 11 | 2.080 |
Why?
|
| Caloric Restriction | 15 | 2024 | 97 | 2.060 |
Why?
|
| Male | 220 | 2025 | 65072 | 2.030 |
Why?
|
| Computer Simulation | 25 | 2024 | 699 | 2.020 |
Why?
|
| Female | 227 | 2025 | 70809 | 2.020 |
Why?
|
| Anti-Obesity Agents | 12 | 2023 | 43 | 2.000 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 17 | 2011 | 1046 | 1.980 |
Why?
|
| Quantitative Trait Loci | 16 | 2012 | 313 | 1.960 |
Why?
|
| Nutritional Status | 7 | 2023 | 329 | 1.940 |
Why?
|
| Health Promotion | 7 | 2020 | 404 | 1.880 |
Why?
|
| Breast Feeding | 8 | 2025 | 240 | 1.880 |
Why?
|
| Periodicals as Topic | 9 | 2025 | 194 | 1.840 |
Why?
|
| Environment | 9 | 2018 | 154 | 1.780 |
Why?
|
| Obesity, Morbid | 7 | 2018 | 212 | 1.760 |
Why?
|
| Cluster Analysis | 14 | 2023 | 436 | 1.740 |
Why?
|
| Cardiovascular Diseases | 14 | 2023 | 2062 | 1.740 |
Why?
|
| Gardening | 2 | 2025 | 17 | 1.710 |
Why?
|
| Reproducibility of Results | 31 | 2025 | 3024 | 1.710 |
Why?
|
| Motor Activity | 12 | 2018 | 521 | 1.700 |
Why?
|
| Adult | 131 | 2025 | 31624 | 1.690 |
Why?
|
| Choice Behavior | 5 | 2023 | 132 | 1.670 |
Why?
|
| Vegetables | 6 | 2023 | 274 | 1.670 |
Why?
|
| Beverages | 7 | 2019 | 102 | 1.630 |
Why?
|
| Dietary Fats | 12 | 2020 | 296 | 1.590 |
Why?
|
| Reproduction | 8 | 2024 | 226 | 1.570 |
Why?
|
| Regression Analysis | 28 | 2024 | 801 | 1.420 |
Why?
|
| Causality | 7 | 2023 | 92 | 1.420 |
Why?
|
| Research | 6 | 2024 | 267 | 1.370 |
Why?
|
| Spinal Cord Injuries | 5 | 2022 | 261 | 1.360 |
Why?
|
| Animals | 109 | 2025 | 34996 | 1.350 |
Why?
|
| Obesity, Abdominal | 3 | 2020 | 40 | 1.340 |
Why?
|
| Fruit | 7 | 2020 | 234 | 1.320 |
Why?
|
| Waist Circumference | 6 | 2018 | 95 | 1.300 |
Why?
|
| Chromosome Mapping | 18 | 2010 | 1098 | 1.290 |
Why?
|
| Models, Biological | 14 | 2024 | 1458 | 1.290 |
Why?
|
| Motivation | 5 | 2025 | 329 | 1.280 |
Why?
|
| Malus | 2 | 2019 | 12 | 1.260 |
Why?
|
| Dietary Carbohydrates | 6 | 2022 | 118 | 1.250 |
Why?
|
| Observational Studies as Topic | 6 | 2024 | 106 | 1.240 |
Why?
|
| Scientific Experimental Error | 2 | 2020 | 2 | 1.230 |
Why?
|
| Dietary Proteins | 5 | 2025 | 252 | 1.190 |
Why?
|
| Fatty Acids, Unsaturated | 2 | 2025 | 66 | 1.190 |
Why?
|
| Sleep | 3 | 2025 | 373 | 1.160 |
Why?
|
| Exercise Therapy | 5 | 2023 | 184 | 1.150 |
Why?
|
| Retraction of Publication as Topic | 2 | 2020 | 4 | 1.150 |
Why?
|
| Science | 4 | 2024 | 37 | 1.130 |
Why?
|
| Diabetes Mellitus, Type 2 | 12 | 2022 | 1413 | 1.120 |
Why?
|
| Dementia | 2 | 2023 | 475 | 1.120 |
Why?
|
| Mice, Inbred C57BL | 31 | 2024 | 4767 | 1.120 |
Why?
|
| Metformin | 3 | 2019 | 165 | 1.110 |
Why?
|
| Editorial Policies | 2 | 2020 | 52 | 1.090 |
Why?
|
| Diet, Carbohydrate-Restricted | 5 | 2024 | 29 | 1.090 |
Why?
|
| Sweetening Agents | 4 | 2012 | 37 | 1.080 |
Why?
|
| Waist-Hip Ratio | 6 | 2018 | 59 | 1.070 |
Why?
|
| Selection, Genetic | 7 | 2018 | 165 | 1.070 |
Why?
|
| Sample Size | 6 | 2022 | 88 | 1.050 |
Why?
|
| Peer Review, Research | 4 | 2016 | 44 | 1.040 |
Why?
|
| Bayes Theorem | 14 | 2024 | 309 | 1.040 |
Why?
|
| Data Collection | 4 | 2018 | 389 | 1.030 |
Why?
|
| Milk, Human | 3 | 2025 | 310 | 1.020 |
Why?
|
| Mice | 57 | 2024 | 18572 | 1.020 |
Why?
|
| Appetite Regulation | 6 | 2014 | 44 | 1.020 |
Why?
|
| Bariatric Surgery | 2 | 2018 | 140 | 1.000 |
Why?
|
| Health Behavior | 7 | 2021 | 399 | 1.000 |
Why?
|
| Behavior Therapy | 3 | 2025 | 269 | 0.990 |
Why?
|
| Middle Aged | 90 | 2025 | 28895 | 0.990 |
Why?
|
| Mortality | 7 | 2024 | 257 | 0.990 |
Why?
|
| Research Report | 3 | 2024 | 72 | 0.980 |
Why?
|
| Anthropometry | 10 | 2020 | 206 | 0.980 |
Why?
|
| Adolescent | 51 | 2025 | 20560 | 0.960 |
Why?
|
| Neuralgia | 3 | 2022 | 49 | 0.960 |
Why?
|
| Hypoglycemic Agents | 6 | 2019 | 482 | 0.950 |
Why?
|
| Ghrelin | 4 | 2023 | 56 | 0.950 |
Why?
|
| Diet, High-Protein | 1 | 2025 | 5 | 0.940 |
Why?
|
| Absorptiometry, Photon | 16 | 2019 | 205 | 0.930 |
Why?
|
| Enteral Nutrition | 2 | 2018 | 269 | 0.910 |
Why?
|
| Genetic Linkage | 6 | 2006 | 475 | 0.910 |
Why?
|
| Publishing | 7 | 2025 | 112 | 0.910 |
Why?
|
| School Health Services | 3 | 2015 | 102 | 0.900 |
Why?
|
| Child | 44 | 2025 | 25835 | 0.900 |
Why?
|
| Cholesterol | 9 | 2023 | 559 | 0.900 |
Why?
|
| Health Policy | 4 | 2017 | 230 | 0.890 |
Why?
|
| Statistics, Nonparametric | 5 | 2021 | 440 | 0.890 |
Why?
|
| Lactation | 3 | 2024 | 198 | 0.880 |
Why?
|
| Genetic Predisposition to Disease | 15 | 2018 | 3358 | 0.870 |
Why?
|
| Parenting | 3 | 2018 | 349 | 0.860 |
Why?
|
| Cooking | 2 | 2023 | 38 | 0.860 |
Why?
|
| Physical Fitness | 2 | 2023 | 93 | 0.850 |
Why?
|
| Genome-Wide Association Study | 7 | 2018 | 1831 | 0.850 |
Why?
|
| Writing | 2 | 2024 | 66 | 0.850 |
Why?
|
| Antipsychotic Agents | 8 | 2013 | 380 | 0.840 |
Why?
|
| Models, Theoretical | 6 | 2018 | 392 | 0.830 |
Why?
|
| Dietary Sucrose | 3 | 2013 | 42 | 0.830 |
Why?
|
| Satiation | 3 | 2024 | 26 | 0.810 |
Why?
|
| Aged | 55 | 2025 | 21386 | 0.810 |
Why?
|
| Epistasis, Genetic | 9 | 2008 | 102 | 0.810 |
Why?
|
| Risk Factors | 36 | 2024 | 10912 | 0.810 |
Why?
|
| Nutrition Assessment | 3 | 2021 | 136 | 0.810 |
Why?
|
| Evidence-Based Practice | 3 | 2018 | 115 | 0.810 |
Why?
|
| Soccer | 1 | 2023 | 9 | 0.800 |
Why?
|
| Affective Symptoms | 1 | 2023 | 63 | 0.800 |
Why?
|
| Creativity | 1 | 2023 | 14 | 0.800 |
Why?
|
| Young Adult | 27 | 2024 | 9949 | 0.800 |
Why?
|
| Appetite | 1 | 2023 | 35 | 0.800 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 6 | 2019 | 75 | 0.790 |
Why?
|
| Perception | 6 | 2021 | 237 | 0.790 |
Why?
|
| Music | 1 | 2023 | 17 | 0.790 |
Why?
|
| Actinidia | 1 | 2022 | 3 | 0.790 |
Why?
|
| Adiposity | 12 | 2021 | 207 | 0.780 |
Why?
|
| Polymorphism, Genetic | 7 | 2006 | 804 | 0.780 |
Why?
|
| Body Height | 10 | 2016 | 227 | 0.780 |
Why?
|
| Information Dissemination | 2 | 2025 | 199 | 0.780 |
Why?
|
| Body Constitution | 11 | 2005 | 42 | 0.780 |
Why?
|
| Mannans | 2 | 2015 | 15 | 0.780 |
Why?
|
| Health Education | 2 | 2015 | 232 | 0.770 |
Why?
|
| Prunus dulcis | 1 | 2022 | 1 | 0.770 |
Why?
|
| Genome, Human | 7 | 2012 | 1332 | 0.760 |
Why?
|
| Solanum tuberosum | 1 | 2022 | 16 | 0.760 |
Why?
|
| Ascorbic Acid | 1 | 2022 | 77 | 0.760 |
Why?
|
| Muscle, Skeletal | 10 | 2021 | 1042 | 0.760 |
Why?
|
| Pilot Projects | 8 | 2023 | 1454 | 0.760 |
Why?
|
| Cross-Sectional Studies | 23 | 2025 | 3745 | 0.750 |
Why?
|
| Cellular Senescence | 7 | 2024 | 201 | 0.750 |
Why?
|
| Quantitative Trait, Heritable | 6 | 2011 | 111 | 0.750 |
Why?
|
| Elephants | 5 | 2025 | 44 | 0.750 |
Why?
|
| Educational Status | 4 | 2023 | 295 | 0.740 |
Why?
|
| Carbonated Beverages | 2 | 2013 | 11 | 0.740 |
Why?
|
| Islet Amyloid Polypeptide | 1 | 2021 | 13 | 0.740 |
Why?
|
| Child Nutritional Physiological Phenomena | 4 | 2015 | 175 | 0.740 |
Why?
|
| Circadian Rhythm | 3 | 2022 | 316 | 0.730 |
Why?
|
| Phenotype | 28 | 2021 | 4545 | 0.730 |
Why?
|
| Linear Models | 10 | 2022 | 713 | 0.730 |
Why?
|
| Research Support as Topic | 3 | 2011 | 63 | 0.720 |
Why?
|
| SAIDS Vaccines | 5 | 2019 | 11 | 0.720 |
Why?
|
| Computational Biology | 5 | 2006 | 875 | 0.710 |
Why?
|
| Food Supply | 3 | 2023 | 101 | 0.710 |
Why?
|
| Phytotherapy | 3 | 2015 | 50 | 0.710 |
Why?
|
| Wearable Electronic Devices | 1 | 2023 | 108 | 0.710 |
Why?
|
| Diet, Carbohydrate Loading | 1 | 2021 | 3 | 0.710 |
Why?
|
| Gene Expression Profiling | 14 | 2016 | 1881 | 0.700 |
Why?
|
| Consensus | 5 | 2023 | 656 | 0.690 |
Why?
|
| Coffee | 1 | 2021 | 30 | 0.690 |
Why?
|
| Evidence-Based Medicine | 5 | 2017 | 672 | 0.690 |
Why?
|
| Clinical Trials as Topic | 6 | 2022 | 1153 | 0.680 |
Why?
|
| Blueberry Plants | 1 | 2020 | 6 | 0.680 |
Why?
|
| Diet, Paleolithic | 1 | 2020 | 1 | 0.670 |
Why?
|
| Food Preferences | 5 | 2017 | 118 | 0.670 |
Why?
|
| Mothers | 2 | 2023 | 374 | 0.670 |
Why?
|
| United States | 40 | 2025 | 11631 | 0.660 |
Why?
|
| Self Report | 8 | 2019 | 552 | 0.660 |
Why?
|
| Plant Extracts | 2 | 2021 | 135 | 0.660 |
Why?
|
| Moxibustion | 1 | 2020 | 1 | 0.660 |
Why?
|
| Auriculotherapy | 1 | 2020 | 1 | 0.660 |
Why?
|
| United States Environmental Protection Agency | 1 | 2020 | 8 | 0.660 |
Why?
|
| Cannabinoids | 1 | 2020 | 33 | 0.650 |
Why?
|
| Goals | 4 | 2020 | 134 | 0.650 |
Why?
|
| Insulin | 12 | 2024 | 1211 | 0.650 |
Why?
|
| Social Marketing | 1 | 2020 | 9 | 0.650 |
Why?
|
| Nuclear Family | 1 | 2020 | 51 | 0.650 |
Why?
|
| Genetic Techniques | 5 | 2009 | 104 | 0.650 |
Why?
|
| Correspondence as Topic | 1 | 2020 | 12 | 0.640 |
Why?
|
| Genotype | 23 | 2021 | 2706 | 0.640 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2024 | 331 | 0.640 |
Why?
|
| Research Personnel | 2 | 2020 | 136 | 0.640 |
Why?
|
| Indians, North American | 1 | 2020 | 68 | 0.640 |
Why?
|
| Government Regulation | 1 | 2020 | 43 | 0.640 |
Why?
|
| Terminology as Topic | 4 | 2010 | 232 | 0.630 |
Why?
|
| Pyrus | 1 | 2019 | 1 | 0.630 |
Why?
|
| Olea | 1 | 2019 | 2 | 0.630 |
Why?
|
| Hospital Design and Construction | 4 | 2025 | 11 | 0.630 |
Why?
|
| Cocos | 1 | 2019 | 3 | 0.630 |
Why?
|
| Circadian Clocks | 1 | 2020 | 82 | 0.620 |
Why?
|
| Episiotomy | 1 | 2019 | 17 | 0.620 |
Why?
|
| Food Deprivation | 1 | 2019 | 34 | 0.620 |
Why?
|
| Tea | 1 | 2019 | 18 | 0.620 |
Why?
|
| Interior Design and Furnishings | 3 | 2025 | 4 | 0.620 |
Why?
|
| Fathers | 1 | 2020 | 72 | 0.610 |
Why?
|
| Child Nutrition Sciences | 1 | 2019 | 19 | 0.610 |
Why?
|
| Genetic Markers | 13 | 2012 | 619 | 0.610 |
Why?
|
| Practice Guidelines as Topic | 5 | 2021 | 1313 | 0.610 |
Why?
|
| Metabolic Syndrome | 5 | 2015 | 365 | 0.610 |
Why?
|
| Vitamin D | 1 | 2020 | 180 | 0.600 |
Why?
|
| Endocrine Disruptors | 2 | 2010 | 53 | 0.600 |
Why?
|
| Snacks | 1 | 2019 | 20 | 0.600 |
Why?
|
| Kynurenine | 1 | 2019 | 26 | 0.600 |
Why?
|
| Heredity | 2 | 2018 | 16 | 0.600 |
Why?
|
| Simian Immunodeficiency Virus | 6 | 2019 | 99 | 0.590 |
Why?
|
| Motivational Interviewing | 1 | 2019 | 48 | 0.590 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2015 | 897 | 0.590 |
Why?
|
| Cardiovascular System | 1 | 2020 | 107 | 0.590 |
Why?
|
| Accidents, Traffic | 4 | 2013 | 109 | 0.580 |
Why?
|
| Video Games | 1 | 2020 | 98 | 0.580 |
Why?
|
| Genomics | 5 | 2007 | 1652 | 0.580 |
Why?
|
| Air Pollution, Indoor | 1 | 2018 | 34 | 0.580 |
Why?
|
| Linkage Disequilibrium | 6 | 2009 | 317 | 0.580 |
Why?
|
| Physical Endurance | 3 | 2015 | 47 | 0.570 |
Why?
|
| Sodium-Glucose Transporter 2 | 1 | 2018 | 18 | 0.570 |
Why?
|
| Models, Educational | 1 | 2018 | 73 | 0.570 |
Why?
|
| Homosexuality, Female | 1 | 2018 | 3 | 0.570 |
Why?
|
| Home Care Services | 1 | 2019 | 81 | 0.570 |
Why?
|
| Pregnancy Complications | 1 | 2023 | 554 | 0.560 |
Why?
|
| Photography | 1 | 2018 | 87 | 0.560 |
Why?
|
| Nutrition Surveys | 11 | 2016 | 314 | 0.550 |
Why?
|
| Nutritional Physiological Phenomena | 4 | 2016 | 95 | 0.550 |
Why?
|
| Genetics | 2 | 2009 | 24 | 0.550 |
Why?
|
| Policy Making | 2 | 2017 | 61 | 0.540 |
Why?
|
| Maternal Behavior | 2 | 2015 | 71 | 0.540 |
Why?
|
| Surveys and Questionnaires | 11 | 2025 | 3983 | 0.540 |
Why?
|
| Genetic Variation | 9 | 2012 | 1583 | 0.530 |
Why?
|
| Cause of Death | 6 | 2019 | 503 | 0.530 |
Why?
|
| Diet, Fat-Restricted | 3 | 2015 | 40 | 0.530 |
Why?
|
| Demography | 1 | 2017 | 242 | 0.520 |
Why?
|
| Diabetes Mellitus | 7 | 2023 | 922 | 0.520 |
Why?
|
| Cognition | 6 | 2024 | 814 | 0.510 |
Why?
|
| Sexual and Gender Minorities | 1 | 2018 | 72 | 0.510 |
Why?
|
| Sex Factors | 18 | 2024 | 1350 | 0.510 |
Why?
|
| Gastric Bypass | 1 | 2017 | 80 | 0.510 |
Why?
|
| Hunger | 3 | 2013 | 43 | 0.510 |
Why?
|
| Life Style | 7 | 2023 | 455 | 0.500 |
Why?
|
| Insulin Resistance | 6 | 2022 | 703 | 0.500 |
Why?
|
| Cytokines | 3 | 2019 | 1368 | 0.500 |
Why?
|
| Poverty | 3 | 2017 | 437 | 0.500 |
Why?
|
| Risk | 4 | 2013 | 763 | 0.500 |
Why?
|
| Public Health Systems Research | 1 | 2016 | 1 | 0.500 |
Why?
|
| Fructose | 3 | 2011 | 65 | 0.500 |
Why?
|
| Brassica | 1 | 2016 | 16 | 0.500 |
Why?
|
| Dietary Fiber | 2 | 2015 | 82 | 0.500 |
Why?
|
| Publications | 3 | 2020 | 35 | 0.490 |
Why?
|
| Law Enforcement | 1 | 2016 | 16 | 0.490 |
Why?
|
| Police | 1 | 2016 | 14 | 0.490 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2021 | 422 | 0.480 |
Why?
|
| Postprandial Period | 2 | 2019 | 91 | 0.480 |
Why?
|
| Fast Foods | 2 | 2014 | 35 | 0.470 |
Why?
|
| Amorphophallus | 1 | 2015 | 1 | 0.470 |
Why?
|
| Alleles | 10 | 2018 | 1683 | 0.460 |
Why?
|
| Phentermine | 2 | 2011 | 8 | 0.460 |
Why?
|
| Rehabilitation | 1 | 2015 | 23 | 0.460 |
Why?
|
| Food Labeling | 2 | 2011 | 11 | 0.460 |
Why?
|
| Restaurants | 1 | 2014 | 15 | 0.450 |
Why?
|
| Cross-Over Studies | 7 | 2019 | 328 | 0.450 |
Why?
|
| Sleep Deprivation | 1 | 2015 | 45 | 0.450 |
Why?
|
| Patient Participation | 2 | 2015 | 240 | 0.450 |
Why?
|
| Play and Playthings | 1 | 2014 | 18 | 0.450 |
Why?
|
| Algorithms | 10 | 2014 | 1723 | 0.450 |
Why?
|
| DNA, Mitochondrial | 3 | 2021 | 243 | 0.440 |
Why?
|
| Diet, High-Fat | 4 | 2024 | 255 | 0.440 |
Why?
|
| Gene Expression | 2 | 2019 | 1564 | 0.440 |
Why?
|
| Rats | 9 | 2022 | 3620 | 0.440 |
Why?
|
| Publication Bias | 3 | 2017 | 17 | 0.440 |
Why?
|
| Quality of Life | 5 | 2025 | 2152 | 0.440 |
Why?
|
| Crowdsourcing | 1 | 2014 | 14 | 0.440 |
Why?
|
| Drug Prescriptions | 1 | 2016 | 238 | 0.440 |
Why?
|
| Nuts | 1 | 2014 | 17 | 0.430 |
Why?
|
| Genetics, Population | 4 | 2010 | 188 | 0.430 |
Why?
|
| Fabaceae | 1 | 2014 | 27 | 0.430 |
Why?
|
| Aged, 80 and over | 17 | 2025 | 7112 | 0.420 |
Why?
|
| Diagnostic Self Evaluation | 2 | 2012 | 23 | 0.420 |
Why?
|
| Behavior, Animal | 3 | 2021 | 507 | 0.420 |
Why?
|
| Analysis of Variance | 12 | 2015 | 1009 | 0.420 |
Why?
|
| Comprehension | 1 | 2014 | 81 | 0.420 |
Why?
|
| Reproductive Behavior | 1 | 2013 | 7 | 0.420 |
Why?
|
| Body Fat Distribution | 2 | 2011 | 32 | 0.420 |
Why?
|
| Gait | 1 | 2015 | 140 | 0.420 |
Why?
|
| Depression | 1 | 2023 | 1351 | 0.420 |
Why?
|
| Critical Illness | 1 | 2018 | 617 | 0.420 |
Why?
|
| Treatment Outcome | 14 | 2022 | 13020 | 0.420 |
Why?
|
| Stress, Psychological | 2 | 2018 | 578 | 0.410 |
Why?
|
| Autism Spectrum Disorder | 1 | 2019 | 430 | 0.410 |
Why?
|
| Gene Products, vif | 3 | 2019 | 7 | 0.410 |
Why?
|
| Authorship | 1 | 2013 | 30 | 0.410 |
Why?
|
| Gene Products, nef | 3 | 2019 | 17 | 0.410 |
Why?
|
| Cholesterol, LDL | 2 | 2015 | 602 | 0.410 |
Why?
|
| Double-Blind Method | 8 | 2019 | 1649 | 0.410 |
Why?
|
| Abdominal Fat | 3 | 2013 | 22 | 0.400 |
Why?
|
| Longitudinal Studies | 12 | 2024 | 1502 | 0.400 |
Why?
|
| Inheritance Patterns | 1 | 2013 | 131 | 0.400 |
Why?
|
| Cookbooks as Topic | 1 | 2012 | 2 | 0.400 |
Why?
|
| Appetite Depressants | 2 | 2010 | 23 | 0.400 |
Why?
|
| Genome | 2 | 2006 | 502 | 0.390 |
Why?
|
| Epidemiologic Studies | 2 | 2010 | 42 | 0.390 |
Why?
|
| Crohn Disease | 1 | 2016 | 291 | 0.390 |
Why?
|
| Cold Temperature | 3 | 2018 | 83 | 0.390 |
Why?
|
| Walking | 1 | 2015 | 232 | 0.390 |
Why?
|
| Life Expectancy | 1 | 2013 | 59 | 0.390 |
Why?
|
| Life Tables | 1 | 2012 | 27 | 0.380 |
Why?
|
| Glutamate Decarboxylase | 2 | 2018 | 42 | 0.380 |
Why?
|
| Drug Approval | 1 | 2012 | 45 | 0.380 |
Why?
|
| Pregnancy | 7 | 2024 | 7568 | 0.380 |
Why?
|
| Fertility | 2 | 2016 | 260 | 0.380 |
Why?
|
| Medication Adherence | 1 | 2015 | 326 | 0.380 |
Why?
|
| Plethysmography | 1 | 2012 | 36 | 0.380 |
Why?
|
| Age Factors | 14 | 2021 | 2930 | 0.380 |
Why?
|
| Air | 1 | 2012 | 24 | 0.370 |
Why?
|
| Blood Pressure | 8 | 2016 | 1373 | 0.370 |
Why?
|
| Chronic Disease | 1 | 2016 | 1229 | 0.370 |
Why?
|
| Inflammation | 2 | 2021 | 1526 | 0.370 |
Why?
|
| Adoption | 1 | 2011 | 18 | 0.360 |
Why?
|
| Lipoproteins, LDL | 2 | 2011 | 137 | 0.360 |
Why?
|
| Mental Disorders | 3 | 2025 | 893 | 0.360 |
Why?
|
| Disease | 2 | 2014 | 128 | 0.360 |
Why?
|
| Heart Rate | 3 | 2023 | 573 | 0.360 |
Why?
|
| Drosophila melanogaster | 5 | 2018 | 841 | 0.360 |
Why?
|
| Family | 5 | 2022 | 595 | 0.360 |
Why?
|
| Metabolic Diseases | 3 | 2011 | 139 | 0.360 |
Why?
|
| Operating Rooms | 2 | 2025 | 76 | 0.360 |
Why?
|
| Basal Metabolism | 6 | 2013 | 94 | 0.350 |
Why?
|
| Diseases in Twins | 3 | 2005 | 100 | 0.350 |
Why?
|
| Cyclobutanes | 1 | 2010 | 6 | 0.350 |
Why?
|
| Depressive Disorder | 1 | 2014 | 481 | 0.350 |
Why?
|
| Myocardial Ischemia | 1 | 2014 | 341 | 0.350 |
Why?
|
| Fractures, Bone | 1 | 2013 | 206 | 0.340 |
Why?
|
| Polymorphism, Single Nucleotide | 13 | 2015 | 2851 | 0.340 |
Why?
|
| Patient Education as Topic | 1 | 2014 | 460 | 0.340 |
Why?
|
| Macaca mulatta | 10 | 2019 | 506 | 0.340 |
Why?
|
| Pediatrics | 2 | 2025 | 1215 | 0.340 |
Why?
|
| Dioxins | 1 | 2010 | 4 | 0.340 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 3 | 2009 | 277 | 0.340 |
Why?
|
| Telomere | 3 | 2019 | 222 | 0.340 |
Why?
|
| Hydrocarbons, Chlorinated | 1 | 2010 | 14 | 0.330 |
Why?
|
| Models, Animal | 3 | 2018 | 471 | 0.330 |
Why?
|
| Primary Health Care | 2 | 2021 | 800 | 0.330 |
Why?
|
| Motor Vehicles | 1 | 2010 | 11 | 0.330 |
Why?
|
| Biomimetics | 1 | 2010 | 18 | 0.330 |
Why?
|
| Deoxyglucose | 1 | 2010 | 43 | 0.330 |
Why?
|
| Rats, Inbred F344 | 1 | 2010 | 97 | 0.320 |
Why?
|
| Stilbenes | 1 | 2010 | 38 | 0.320 |
Why?
|
| Wounds and Injuries | 2 | 2012 | 392 | 0.320 |
Why?
|
| Guidelines as Topic | 3 | 2019 | 197 | 0.320 |
Why?
|
| Software | 4 | 2012 | 729 | 0.320 |
Why?
|
| Temperature | 3 | 2018 | 304 | 0.320 |
Why?
|
| Histocompatibility Antigens Class I | 4 | 2019 | 105 | 0.310 |
Why?
|
| Receptors, Cell Surface | 2 | 2002 | 452 | 0.310 |
Why?
|
| Patient Compliance | 5 | 2014 | 475 | 0.310 |
Why?
|
| Lipid Metabolism | 2 | 2011 | 389 | 0.310 |
Why?
|
| Meta-Analysis as Topic | 2 | 2008 | 171 | 0.310 |
Why?
|
| Body Size | 4 | 2019 | 69 | 0.310 |
Why?
|
| Homeostasis | 5 | 2018 | 730 | 0.310 |
Why?
|
| Thermogenesis | 2 | 2020 | 50 | 0.310 |
Why?
|
| Chromosomes, Human, Pair 11 | 3 | 2010 | 87 | 0.300 |
Why?
|
| Infant | 9 | 2025 | 13198 | 0.300 |
Why?
|
| Breast Neoplasms | 3 | 2019 | 2683 | 0.300 |
Why?
|
| Language | 1 | 2010 | 225 | 0.300 |
Why?
|
| Child, Preschool | 19 | 2023 | 14862 | 0.300 |
Why?
|
| Logistic Models | 8 | 2013 | 1840 | 0.300 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2015 | 742 | 0.290 |
Why?
|
| Attitude to Health | 2 | 2003 | 260 | 0.290 |
Why?
|
| C-Reactive Protein | 2 | 2009 | 466 | 0.290 |
Why?
|
| Crosses, Genetic | 6 | 2006 | 162 | 0.290 |
Why?
|
| Industry | 1 | 2008 | 29 | 0.290 |
Why?
|
| Follow-Up Studies | 8 | 2018 | 5405 | 0.290 |
Why?
|
| Acclimatization | 3 | 2018 | 24 | 0.290 |
Why?
|
| Observation | 1 | 2008 | 43 | 0.290 |
Why?
|
| Soy Foods | 1 | 2008 | 10 | 0.290 |
Why?
|
| Patients | 1 | 2009 | 127 | 0.290 |
Why?
|
| Glucose | 4 | 2022 | 911 | 0.290 |
Why?
|
| Body Temperature | 2 | 2024 | 128 | 0.290 |
Why?
|
| Socioeconomic Factors | 5 | 2023 | 901 | 0.280 |
Why?
|
| Schizophrenia | 2 | 2003 | 332 | 0.280 |
Why?
|
| Cohort Studies | 12 | 2013 | 5153 | 0.280 |
Why?
|
| Parent-Child Relations | 3 | 2014 | 253 | 0.280 |
Why?
|
| Suicide, Attempted | 1 | 2009 | 154 | 0.280 |
Why?
|
| Environmental Pollutants | 1 | 2008 | 79 | 0.280 |
Why?
|
| Birth Weight | 2 | 2023 | 354 | 0.280 |
Why?
|
| Smoking Cessation | 2 | 2006 | 191 | 0.270 |
Why?
|
| Glucose Tolerance Test | 3 | 2024 | 223 | 0.270 |
Why?
|
| Oxidative Stress | 3 | 2024 | 800 | 0.270 |
Why?
|
| Corn Oil | 1 | 2007 | 10 | 0.270 |
Why?
|
| Workflow | 2 | 2025 | 134 | 0.270 |
Why?
|
| Gene Frequency | 7 | 2015 | 751 | 0.270 |
Why?
|
| Headache | 1 | 2008 | 109 | 0.270 |
Why?
|
| Twins, Monozygotic | 5 | 2012 | 129 | 0.260 |
Why?
|
| Alzheimer Disease | 3 | 2015 | 865 | 0.260 |
Why?
|
| Odds Ratio | 7 | 2016 | 1256 | 0.260 |
Why?
|
| Prevalence | 11 | 2018 | 2665 | 0.260 |
Why?
|
| Databases, Genetic | 2 | 2008 | 500 | 0.260 |
Why?
|
| Survival Analysis | 6 | 2018 | 1570 | 0.260 |
Why?
|
| Triiodothyronine | 2 | 2025 | 60 | 0.260 |
Why?
|
| Gene Expression Regulation | 7 | 2021 | 2446 | 0.260 |
Why?
|
| Suicide | 1 | 2009 | 203 | 0.260 |
Why?
|
| Quality Control | 3 | 2018 | 123 | 0.260 |
Why?
|
| Ethics, Research | 2 | 2024 | 55 | 0.260 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2006 | 35 | 0.260 |
Why?
|
| Bupropion | 1 | 2006 | 29 | 0.260 |
Why?
|
| Cattle | 2 | 2025 | 576 | 0.250 |
Why?
|
| Carrier Proteins | 2 | 2002 | 1049 | 0.250 |
Why?
|
| Food, Formulated | 2 | 2024 | 52 | 0.250 |
Why?
|
| Sex Characteristics | 5 | 2016 | 330 | 0.250 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2019 | 449 | 0.250 |
Why?
|
| Animals, Zoo | 3 | 2023 | 17 | 0.250 |
Why?
|
| Genes | 1 | 2007 | 314 | 0.250 |
Why?
|
| Uric Acid | 2 | 2018 | 110 | 0.250 |
Why?
|
| Hyperinsulinism | 2 | 2022 | 64 | 0.250 |
Why?
|
| Health Surveys | 6 | 2013 | 259 | 0.250 |
Why?
|
| Smoking | 4 | 2012 | 942 | 0.240 |
Why?
|
| Stroke | 1 | 2014 | 1068 | 0.240 |
Why?
|
| Physicians | 2 | 2024 | 635 | 0.240 |
Why?
|
| Risperidone | 4 | 2013 | 59 | 0.240 |
Why?
|
| Equipment Failure Analysis | 1 | 2006 | 86 | 0.240 |
Why?
|
| Patients' Rooms | 1 | 2025 | 10 | 0.240 |
Why?
|
| Reference Standards | 2 | 2006 | 242 | 0.240 |
Why?
|
| Red Meat | 1 | 2025 | 9 | 0.240 |
Why?
|
| DNA Copy Number Variations | 3 | 2021 | 1035 | 0.240 |
Why?
|
| Parents | 3 | 2019 | 1076 | 0.240 |
Why?
|
| Cyclic GMP-Dependent Protein Kinases | 1 | 2005 | 13 | 0.240 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2005 | 71 | 0.240 |
Why?
|
| Synephrine | 1 | 2005 | 1 | 0.230 |
Why?
|
| Citrus | 1 | 2005 | 7 | 0.230 |
Why?
|
| Proportional Hazards Models | 6 | 2025 | 1451 | 0.230 |
Why?
|
| Facility Design and Construction | 1 | 2025 | 5 | 0.230 |
Why?
|
| Bone Density | 6 | 2012 | 369 | 0.230 |
Why?
|
| Drug Combinations | 4 | 2011 | 279 | 0.230 |
Why?
|
| Brain-Derived Neurotrophic Factor | 2 | 2024 | 99 | 0.230 |
Why?
|
| Proteomics | 2 | 2006 | 594 | 0.230 |
Why?
|
| Biology | 1 | 2005 | 27 | 0.230 |
Why?
|
| Time Factors | 9 | 2018 | 6457 | 0.230 |
Why?
|
| Alkaloids | 1 | 2005 | 37 | 0.230 |
Why?
|
| Skin Neoplasms | 1 | 2012 | 897 | 0.230 |
Why?
|
| Adaptation, Physiological | 3 | 2022 | 278 | 0.230 |
Why?
|
| Plants, Medicinal | 1 | 2004 | 25 | 0.230 |
Why?
|
| Skin Aging | 1 | 2024 | 12 | 0.230 |
Why?
|
| Neoplasms | 4 | 2018 | 2949 | 0.220 |
Why?
|
| Nonprescription Drugs | 1 | 2005 | 54 | 0.220 |
Why?
|
| Narration | 1 | 2024 | 33 | 0.220 |
Why?
|
| Sexual Behavior | 1 | 2006 | 250 | 0.220 |
Why?
|
| Monte Carlo Method | 4 | 2013 | 102 | 0.220 |
Why?
|
| Knowledge | 1 | 2004 | 51 | 0.220 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2025 | 59 | 0.220 |
Why?
|
| Maternal Health | 1 | 2024 | 25 | 0.220 |
Why?
|
| Disease Outbreaks | 1 | 2006 | 329 | 0.220 |
Why?
|
| Root Resorption | 1 | 2024 | 2 | 0.220 |
Why?
|
| Twins | 2 | 1994 | 73 | 0.220 |
Why?
|
| Receptor, Cannabinoid, CB1 | 1 | 2004 | 29 | 0.220 |
Why?
|
| Molecular Biology | 1 | 2004 | 73 | 0.220 |
Why?
|
| Mental Processes | 1 | 2024 | 39 | 0.210 |
Why?
|
| Rest | 3 | 2010 | 66 | 0.210 |
Why?
|
| Quality Assurance, Health Care | 1 | 2006 | 216 | 0.210 |
Why?
|
| Child Development | 3 | 2017 | 289 | 0.210 |
Why?
|
| Interferon Regulatory Factors | 1 | 2024 | 43 | 0.210 |
Why?
|
| Antibodies, Viral | 6 | 2022 | 1205 | 0.210 |
Why?
|
| Bone Resorption | 1 | 2024 | 52 | 0.210 |
Why?
|
| Prospective Studies | 12 | 2020 | 6540 | 0.210 |
Why?
|
| Twins, Dizygotic | 4 | 2012 | 48 | 0.210 |
Why?
|
| Disease Models, Animal | 9 | 2022 | 4695 | 0.210 |
Why?
|
| Oxygen Consumption | 3 | 2015 | 308 | 0.200 |
Why?
|
| Mexican Americans | 1 | 2004 | 168 | 0.200 |
Why?
|
| Problem Solving | 1 | 2023 | 68 | 0.200 |
Why?
|
| Costs and Cost Analysis | 2 | 2018 | 165 | 0.200 |
Why?
|
| Checklist | 2 | 2020 | 96 | 0.200 |
Why?
|
| Mitochondria | 4 | 2021 | 752 | 0.200 |
Why?
|
| Biomarkers | 7 | 2024 | 3391 | 0.200 |
Why?
|
| Dairy Products | 2 | 2020 | 47 | 0.200 |
Why?
|
| Nicaragua | 1 | 2023 | 27 | 0.200 |
Why?
|
| Thailand | 1 | 2023 | 44 | 0.200 |
Why?
|
| Sex Distribution | 4 | 2013 | 324 | 0.200 |
Why?
|
| Canada | 2 | 2022 | 343 | 0.200 |
Why?
|
| Glucocorticoids | 2 | 2025 | 387 | 0.200 |
Why?
|
| Mentors | 1 | 2024 | 164 | 0.200 |
Why?
|
| Leptin | 4 | 2024 | 219 | 0.200 |
Why?
|
| Tablets | 1 | 2022 | 35 | 0.200 |
Why?
|
| Hyperphagia | 2 | 2013 | 46 | 0.190 |
Why?
|
| Predictive Value of Tests | 5 | 2015 | 2303 | 0.190 |
Why?
|
| Glucosides | 2 | 2018 | 48 | 0.190 |
Why?
|
| New York | 3 | 2016 | 72 | 0.190 |
Why?
|
| Hormones | 2 | 2017 | 174 | 0.190 |
Why?
|
| Psychology, Child | 1 | 2002 | 44 | 0.190 |
Why?
|
| Membrane Transport Proteins | 1 | 2003 | 182 | 0.190 |
Why?
|
| Quercetin | 2 | 2021 | 11 | 0.190 |
Why?
|
| Television | 1 | 2023 | 71 | 0.190 |
Why?
|
| Protein Isoforms | 2 | 2019 | 422 | 0.190 |
Why?
|
| Glucose Intolerance | 2 | 2020 | 85 | 0.190 |
Why?
|
| Haplotypes | 5 | 2010 | 545 | 0.190 |
Why?
|
| Dasatinib | 2 | 2021 | 50 | 0.190 |
Why?
|
| Decision Trees | 1 | 2022 | 51 | 0.190 |
Why?
|
| Vitamins | 1 | 2022 | 113 | 0.190 |
Why?
|
| Piperidines | 1 | 2004 | 236 | 0.190 |
Why?
|
| Coronary Disease | 2 | 2025 | 679 | 0.190 |
Why?
|
| Metabolome | 2 | 2022 | 324 | 0.190 |
Why?
|
| Pedigree | 4 | 2012 | 1725 | 0.190 |
Why?
|
| Likelihood Functions | 5 | 2009 | 119 | 0.180 |
Why?
|
| Caffeine | 2 | 2017 | 64 | 0.180 |
Why?
|
| Fasting | 2 | 2021 | 308 | 0.180 |
Why?
|
| Mental Health Services | 1 | 2025 | 281 | 0.180 |
Why?
|
| Decision Making | 3 | 2018 | 693 | 0.180 |
Why?
|
| Toll-Like Receptor 3 | 1 | 2021 | 21 | 0.180 |
Why?
|
| Postmenopause | 2 | 2019 | 153 | 0.180 |
Why?
|
| Obesity Management | 1 | 2021 | 2 | 0.180 |
Why?
|
| Pathogen-Associated Molecular Pattern Molecules | 1 | 2021 | 6 | 0.180 |
Why?
|
| Signal Transduction | 5 | 2021 | 4725 | 0.180 |
Why?
|
| Calorimetry, Indirect | 6 | 2007 | 61 | 0.180 |
Why?
|
| Probability | 3 | 2013 | 323 | 0.180 |
Why?
|
| Diet Therapy | 1 | 2021 | 41 | 0.180 |
Why?
|
| Pyrazoles | 1 | 2004 | 330 | 0.180 |
Why?
|
| Water | 1 | 2022 | 197 | 0.180 |
Why?
|
| Flavonols | 1 | 2021 | 13 | 0.180 |
Why?
|
| Counseling | 1 | 2023 | 235 | 0.180 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 2022 | 124 | 0.180 |
Why?
|
| Osteoarthritis | 1 | 2023 | 103 | 0.180 |
Why?
|
| Child Behavior | 2 | 2014 | 236 | 0.180 |
Why?
|
| Feces | 1 | 2025 | 780 | 0.180 |
Why?
|
| Canagliflozin | 1 | 2020 | 1 | 0.170 |
Why?
|
| Patient Care Team | 1 | 2025 | 572 | 0.170 |
Why?
|
| Selection Bias | 2 | 2014 | 19 | 0.170 |
Why?
|
| HIV-1 | 2 | 2017 | 484 | 0.170 |
Why?
|
| Acarbose | 1 | 2020 | 6 | 0.170 |
Why?
|
| Patient Handoff | 1 | 2021 | 24 | 0.170 |
Why?
|
| Patient Satisfaction | 2 | 2015 | 483 | 0.170 |
Why?
|
| Age Distribution | 2 | 2016 | 433 | 0.170 |
Why?
|
| Fetus | 1 | 2024 | 599 | 0.170 |
Why?
|
| Anesthesia | 1 | 2023 | 208 | 0.170 |
Why?
|
| Genetic Therapy | 1 | 2005 | 720 | 0.170 |
Why?
|
| History, 21st Century | 2 | 2020 | 273 | 0.170 |
Why?
|
| Complementary Therapies | 1 | 2001 | 42 | 0.170 |
Why?
|
| Lipids | 4 | 2008 | 563 | 0.170 |
Why?
|
| Rectum | 2 | 2019 | 114 | 0.170 |
Why?
|
| Death | 1 | 2001 | 78 | 0.170 |
Why?
|
| Hippocampus | 2 | 2024 | 819 | 0.160 |
Why?
|
| Fatty Acids | 2 | 2017 | 365 | 0.160 |
Why?
|
| Courage | 1 | 2020 | 4 | 0.160 |
Why?
|
| Precision Medicine | 1 | 2023 | 361 | 0.160 |
Why?
|
| Recombination, Genetic | 1 | 2021 | 442 | 0.160 |
Why?
|
| Tropism | 1 | 2019 | 11 | 0.160 |
Why?
|
| Health Status | 3 | 2014 | 409 | 0.160 |
Why?
|
| Healthy Lifestyle | 1 | 2020 | 32 | 0.160 |
Why?
|
| Risk Assessment | 6 | 2013 | 3710 | 0.160 |
Why?
|
| Keratins | 1 | 2019 | 52 | 0.160 |
Why?
|
| Access to Information | 2 | 2019 | 43 | 0.160 |
Why?
|
| Encephalitis | 1 | 2021 | 118 | 0.160 |
Why?
|
| Macrophage Migration-Inhibitory Factors | 1 | 2019 | 15 | 0.160 |
Why?
|
| Nutrition Policy | 3 | 2020 | 102 | 0.160 |
Why?
|
| Emergency Service, Hospital | 2 | 2025 | 1161 | 0.160 |
Why?
|
| Fitness Trackers | 1 | 2019 | 14 | 0.160 |
Why?
|
| Affect | 2 | 2019 | 173 | 0.160 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2019 | 41 | 0.150 |
Why?
|
| Multicenter Studies as Topic | 1 | 2020 | 311 | 0.150 |
Why?
|
| Scientific Misconduct | 1 | 2019 | 7 | 0.150 |
Why?
|
| Multivariate Analysis | 7 | 2014 | 1443 | 0.150 |
Why?
|
| Engineering | 1 | 2019 | 7 | 0.150 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 205 | 0.150 |
Why?
|
| Congresses as Topic | 3 | 2014 | 189 | 0.150 |
Why?
|
| Butylene Glycols | 1 | 2018 | 1 | 0.150 |
Why?
|
| Satiety Response | 4 | 2024 | 31 | 0.150 |
Why?
|
| Diet Records | 2 | 2016 | 74 | 0.150 |
Why?
|
| Acetoacetates | 1 | 2018 | 21 | 0.150 |
Why?
|
| Receptors, Peptide | 1 | 1999 | 54 | 0.150 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2019 | 44 | 0.150 |
Why?
|
| Geriatric Assessment | 1 | 2020 | 191 | 0.150 |
Why?
|
| Comorbidity | 3 | 2018 | 1605 | 0.150 |
Why?
|
| Swimming | 1 | 2018 | 29 | 0.150 |
Why?
|
| Developed Countries | 1 | 2019 | 42 | 0.150 |
Why?
|
| PPAR alpha | 1 | 2019 | 55 | 0.150 |
Why?
|
| Adenoviridae Infections | 2 | 2013 | 69 | 0.150 |
Why?
|
| Turkey | 1 | 2018 | 67 | 0.150 |
Why?
|
| Gene Products, env | 1 | 2018 | 17 | 0.150 |
Why?
|
| Alabama | 7 | 2016 | 47 | 0.150 |
Why?
|
| Athletes | 2 | 2021 | 73 | 0.150 |
Why?
|
| Peripheral Nerve Injuries | 1 | 2018 | 40 | 0.150 |
Why?
|
| Fibronectins | 1 | 2018 | 107 | 0.150 |
Why?
|
| Skin | 2 | 2019 | 540 | 0.140 |
Why?
|
| Fenofibrate | 2 | 2009 | 61 | 0.140 |
Why?
|
| Siblings | 2 | 2012 | 202 | 0.140 |
Why?
|
| Australian Capital Territory | 1 | 2017 | 2 | 0.140 |
Why?
|
| Family Health | 2 | 2014 | 257 | 0.140 |
Why?
|
| Weaning | 1 | 2018 | 49 | 0.140 |
Why?
|
| Estrous Cycle | 1 | 2018 | 36 | 0.140 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2018 | 95 | 0.140 |
Why?
|
| Virus Replication | 3 | 2018 | 636 | 0.140 |
Why?
|
| Least-Squares Analysis | 3 | 2012 | 35 | 0.140 |
Why?
|
| Patient Dropouts | 3 | 2015 | 52 | 0.140 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2020 | 304 | 0.140 |
Why?
|
| Genetics, Behavioral | 1 | 1997 | 9 | 0.140 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 1 | 2017 | 9 | 0.140 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2018 | 135 | 0.140 |
Why?
|
| Benzhydryl Compounds | 1 | 2018 | 68 | 0.140 |
Why?
|
| Self Concept | 1 | 1998 | 164 | 0.140 |
Why?
|
| RNA, Messenger | 5 | 2008 | 2687 | 0.140 |
Why?
|
| Australia | 1 | 2017 | 185 | 0.130 |
Why?
|
| Adenosine Triphosphate | 1 | 2018 | 275 | 0.130 |
Why?
|
| Vaccines, Synthetic | 2 | 2019 | 322 | 0.130 |
Why?
|
| Taste Threshold | 1 | 2017 | 1 | 0.130 |
Why?
|
| Caregivers | 1 | 2023 | 598 | 0.130 |
Why?
|
| Interdisciplinary Communication | 1 | 2018 | 133 | 0.130 |
Why?
|
| Databases, Factual | 2 | 2014 | 1230 | 0.130 |
Why?
|
| Growth Hormone | 1 | 2017 | 141 | 0.130 |
Why?
|
| Arousal | 1 | 2017 | 81 | 0.130 |
Why?
|
| Taste | 1 | 2017 | 33 | 0.130 |
Why?
|
| Hypolipidemic Agents | 2 | 2009 | 189 | 0.130 |
Why?
|
| Students | 1 | 2019 | 263 | 0.130 |
Why?
|
| Pharmacogenetics | 3 | 2009 | 200 | 0.130 |
Why?
|
| Cognition Disorders | 1 | 2021 | 571 | 0.130 |
Why?
|
| Hepacivirus | 1 | 2018 | 272 | 0.130 |
Why?
|
| Psychological Tests | 1 | 1997 | 94 | 0.130 |
Why?
|
| Sensitivity and Specificity | 4 | 2014 | 2145 | 0.130 |
Why?
|
| Social Stigma | 1 | 2017 | 85 | 0.130 |
Why?
|
| Visual Analog Scale | 1 | 2016 | 7 | 0.130 |
Why?
|
| Epidemiologic Methods | 1 | 2016 | 100 | 0.130 |
Why?
|
| Cognitive Dysfunction | 1 | 2021 | 313 | 0.130 |
Why?
|
| Adipokines | 1 | 2017 | 72 | 0.130 |
Why?
|
| Parks, Recreational | 1 | 2016 | 4 | 0.130 |
Why?
|
| Central Nervous System Stimulants | 1 | 2017 | 128 | 0.120 |
Why?
|
| Skinfold Thickness | 3 | 2003 | 34 | 0.120 |
Why?
|
| Pain | 1 | 2019 | 461 | 0.120 |
Why?
|
| Muscle Fibers, Skeletal | 2 | 2020 | 110 | 0.120 |
Why?
|
| Down Syndrome | 2 | 1995 | 232 | 0.120 |
Why?
|
| Proteins | 3 | 2014 | 1064 | 0.120 |
Why?
|
| Population Surveillance | 1 | 2018 | 416 | 0.120 |
Why?
|
| Acupressure | 1 | 1995 | 1 | 0.120 |
Why?
|
| Diet, Mediterranean | 1 | 2015 | 21 | 0.120 |
Why?
|
| Programming Languages | 2 | 2006 | 19 | 0.120 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2015 | 50 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2021 | 379 | 0.120 |
Why?
|
| Adolescent Nutritional Physiological Phenomena | 1 | 2015 | 33 | 0.120 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2019 | 300 | 0.120 |
Why?
|
| Viral Regulatory and Accessory Proteins | 1 | 2015 | 39 | 0.120 |
Why?
|
| Ear, External | 1 | 1995 | 23 | 0.120 |
Why?
|
| Brain Neoplasms | 2 | 2021 | 1409 | 0.120 |
Why?
|
| Homozygote | 2 | 2009 | 548 | 0.120 |
Why?
|
| Reimbursement, Incentive | 2 | 2007 | 48 | 0.120 |
Why?
|
| Wound Healing | 1 | 2019 | 480 | 0.120 |
Why?
|
| Spouses | 1 | 1996 | 73 | 0.120 |
Why?
|
| Hyperuricemia | 1 | 2015 | 41 | 0.120 |
Why?
|
| Functional Food | 1 | 2015 | 4 | 0.120 |
Why?
|
| Embryonic and Fetal Development | 1 | 1995 | 130 | 0.120 |
Why?
|
| Meals | 3 | 2023 | 62 | 0.110 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2010 | 1227 | 0.110 |
Why?
|
| Triglycerides | 3 | 2007 | 615 | 0.110 |
Why?
|
| Multiple Sclerosis | 1 | 2019 | 382 | 0.110 |
Why?
|
| Pandemics | 1 | 2022 | 1188 | 0.110 |
Why?
|
| Macrophages | 1 | 2019 | 693 | 0.110 |
Why?
|
| Pregnancy, Animal | 1 | 2015 | 72 | 0.110 |
Why?
|
| Gene-Environment Interaction | 1 | 2015 | 130 | 0.110 |
Why?
|
| Delayed-Action Preparations | 2 | 2011 | 122 | 0.110 |
Why?
|
| Transcription Factors | 3 | 2019 | 2494 | 0.110 |
Why?
|
| Health Services Research | 1 | 2016 | 186 | 0.110 |
Why?
|
| Reference Values | 6 | 2016 | 721 | 0.110 |
Why?
|
| Hepatitis C | 1 | 2018 | 388 | 0.110 |
Why?
|
| HIV Infections | 3 | 2017 | 2063 | 0.110 |
Why?
|
| Research Subjects | 1 | 2014 | 55 | 0.110 |
Why?
|
| Gene Products, gag | 1 | 2014 | 19 | 0.110 |
Why?
|
| Hypertension | 2 | 2011 | 1343 | 0.110 |
Why?
|
| Secondary Prevention | 1 | 2015 | 220 | 0.110 |
Why?
|
| Area Under Curve | 2 | 2012 | 319 | 0.110 |
Why?
|
| Altitude | 1 | 2014 | 23 | 0.110 |
Why?
|
| Brain Injuries | 1 | 2019 | 715 | 0.110 |
Why?
|
| Paternal Behavior | 1 | 2014 | 12 | 0.110 |
Why?
|
| Portion Size | 1 | 2014 | 17 | 0.110 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2014 | 34 | 0.110 |
Why?
|
| United States Food and Drug Administration | 2 | 2012 | 159 | 0.110 |
Why?
|
| Twin Studies as Topic | 2 | 2008 | 14 | 0.110 |
Why?
|
| Africa South of the Sahara | 2 | 2011 | 124 | 0.110 |
Why?
|
| Child Restraint Systems | 1 | 2013 | 7 | 0.100 |
Why?
|
| Coronary Vessels | 1 | 2017 | 548 | 0.100 |
Why?
|
| Mice, Inbred Strains | 4 | 2021 | 309 | 0.100 |
Why?
|
| Adenoviruses, Human | 2 | 2005 | 97 | 0.100 |
Why?
|
| Sirtuin 1 | 1 | 2014 | 54 | 0.100 |
Why?
|
| Seat Belts | 1 | 2013 | 24 | 0.100 |
Why?
|
| Body Image | 1 | 1993 | 43 | 0.100 |
Why?
|
| Electrocardiography | 2 | 2016 | 990 | 0.100 |
Why?
|
| Endpoint Determination | 1 | 2013 | 59 | 0.100 |
Why?
|
| Deuterium | 3 | 2022 | 107 | 0.100 |
Why?
|
| Pelvic Bones | 1 | 2013 | 28 | 0.100 |
Why?
|
| Arthritis, Rheumatoid | 2 | 2009 | 293 | 0.100 |
Why?
|
| Antioxidants | 1 | 2015 | 335 | 0.100 |
Why?
|
| Metabolism | 1 | 2013 | 47 | 0.100 |
Why?
|
| Patient-Centered Care | 1 | 2015 | 233 | 0.100 |
Why?
|
| ROC Curve | 2 | 2012 | 598 | 0.100 |
Why?
|
| Sequence Analysis, DNA | 3 | 2015 | 1807 | 0.100 |
Why?
|
| Internet | 2 | 2006 | 404 | 0.100 |
Why?
|
| Normal Distribution | 1 | 2012 | 20 | 0.100 |
Why?
|
| Gout | 1 | 2015 | 167 | 0.090 |
Why?
|
| Isotopes | 1 | 2012 | 31 | 0.090 |
Why?
|
| Indicator Dilution Techniques | 1 | 2012 | 24 | 0.090 |
Why?
|
| Heart Diseases | 2 | 2007 | 511 | 0.090 |
Why?
|
| Case-Control Studies | 3 | 2009 | 3422 | 0.090 |
Why?
|
| Species Specificity | 2 | 2010 | 544 | 0.090 |
Why?
|
| Body Water | 1 | 2012 | 90 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 1 | 2018 | 1038 | 0.090 |
Why?
|
| Thiazoles | 2 | 2005 | 99 | 0.090 |
Why?
|
| Receptors, Leptin | 2 | 2002 | 42 | 0.090 |
Why?
|
| Nutritive Value | 1 | 2012 | 93 | 0.090 |
Why?
|
| Intra-Abdominal Fat | 1 | 2012 | 60 | 0.090 |
Why?
|
| Urban Health | 2 | 2014 | 78 | 0.090 |
Why?
|
| Pregnancy Outcome | 1 | 2015 | 638 | 0.090 |
Why?
|
| Markov Chains | 3 | 2011 | 99 | 0.090 |
Why?
|
| Body Temperature Regulation | 2 | 2008 | 51 | 0.090 |
Why?
|
| Infant Formula | 2 | 2024 | 100 | 0.090 |
Why?
|
| Streptococcus mutans | 1 | 2011 | 1 | 0.090 |
Why?
|
| Dental Plaque | 1 | 2011 | 6 | 0.090 |
Why?
|
| Menu Planning | 1 | 2011 | 8 | 0.090 |
Why?
|
| Program Evaluation | 1 | 2013 | 455 | 0.090 |
Why?
|
| Callithrix | 1 | 2010 | 14 | 0.090 |
Why?
|
| Kidney Diseases | 1 | 2015 | 488 | 0.090 |
Why?
|
| Diet Surveys | 3 | 2011 | 102 | 0.090 |
Why?
|
| Rats, Wistar | 2 | 2018 | 329 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2011 | 82 | 0.080 |
Why?
|
| Empirical Research | 2 | 2014 | 9 | 0.080 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2021 | 114 | 0.080 |
Why?
|
| Cats | 1 | 2010 | 117 | 0.080 |
Why?
|
| Bibliometrics | 1 | 2010 | 36 | 0.080 |
Why?
|
| Piperazines | 2 | 2005 | 254 | 0.080 |
Why?
|
| Macaca | 1 | 2010 | 62 | 0.080 |
Why?
|
| Pan troglodytes | 1 | 2010 | 75 | 0.080 |
Why?
|
| Preventive Health Services | 1 | 2011 | 62 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2011 | 121 | 0.080 |
Why?
|
| Food Additives | 1 | 2010 | 6 | 0.080 |
Why?
|
| Genetic Vectors | 1 | 2014 | 927 | 0.080 |
Why?
|
| Epidemics | 1 | 2010 | 59 | 0.080 |
Why?
|
| Antimetabolites | 1 | 2010 | 30 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2011 | 148 | 0.080 |
Why?
|
| Primates | 1 | 2010 | 85 | 0.080 |
Why?
|
| Commerce | 1 | 2010 | 57 | 0.080 |
Why?
|
| Dogs | 1 | 2010 | 655 | 0.080 |
Why?
|
| Drug Industry | 1 | 2009 | 48 | 0.080 |
Why?
|
| Biomarkers, Tumor | 2 | 2010 | 1683 | 0.080 |
Why?
|
| Patient Selection | 1 | 2013 | 730 | 0.080 |
Why?
|
| False Negative Reactions | 2 | 2016 | 89 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 2 | 2011 | 1556 | 0.080 |
Why?
|
| Quetiapine Fumarate | 2 | 2007 | 14 | 0.080 |
Why?
|
| Dibenzothiazepines | 2 | 2007 | 12 | 0.080 |
Why?
|
| Nutritional Requirements | 3 | 2018 | 181 | 0.080 |
Why?
|
| Apolipoproteins | 1 | 2009 | 72 | 0.070 |
Why?
|
| Sequence Deletion | 2 | 2021 | 527 | 0.070 |
Why?
|
| Scavenger Receptors, Class B | 1 | 2008 | 12 | 0.070 |
Why?
|
| Lymphatic Metastasis | 1 | 2010 | 443 | 0.070 |
Why?
|
| Societies, Medical | 3 | 2007 | 778 | 0.070 |
Why?
|
| Growth | 1 | 2008 | 102 | 0.070 |
Why?
|
| Sirolimus | 1 | 2010 | 241 | 0.070 |
Why?
|
| Environment, Controlled | 1 | 2008 | 8 | 0.070 |
Why?
|
| Dissent and Disputes | 1 | 2008 | 32 | 0.070 |
Why?
|
| Benzodiazepines | 2 | 2007 | 108 | 0.070 |
Why?
|
| Viremia | 2 | 2019 | 133 | 0.070 |
Why?
|
| Multigene Family | 1 | 2009 | 305 | 0.070 |
Why?
|
| Residence Characteristics | 1 | 2010 | 284 | 0.070 |
Why?
|
| Apolipoprotein A-I | 2 | 2009 | 89 | 0.070 |
Why?
|
| Muscle Cells | 1 | 2007 | 27 | 0.070 |
Why?
|
| Health Status Disparities | 1 | 2011 | 251 | 0.070 |
Why?
|
| Yogurt | 1 | 2007 | 13 | 0.070 |
Why?
|
| Muscle Proteins | 1 | 2010 | 411 | 0.070 |
Why?
|
| Seasons | 2 | 2025 | 331 | 0.070 |
Why?
|
| Chromosomes, Human | 1 | 2008 | 130 | 0.070 |
Why?
|
| Hypertriglyceridemia | 1 | 2009 | 114 | 0.070 |
Why?
|
| Trans Fatty Acids | 1 | 2007 | 11 | 0.070 |
Why?
|
| Massachusetts | 2 | 2015 | 129 | 0.070 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2007 | 36 | 0.070 |
Why?
|
| Confidence Intervals | 1 | 2008 | 278 | 0.070 |
Why?
|
| Extracellular Fluid | 1 | 2007 | 13 | 0.070 |
Why?
|
| United Kingdom | 1 | 2008 | 234 | 0.070 |
Why?
|
| Dietary Fats, Unsaturated | 1 | 2007 | 32 | 0.070 |
Why?
|
| Evolution, Molecular | 1 | 2010 | 698 | 0.070 |
Why?
|
| Women's Health | 2 | 1998 | 148 | 0.070 |
Why?
|
| Enzyme Inhibitors | 1 | 2010 | 589 | 0.070 |
Why?
|
| Antigens, CD | 1 | 2009 | 437 | 0.070 |
Why?
|
| Interprofessional Relations | 1 | 2008 | 156 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 1672 | 0.060 |
Why?
|
| False Positive Reactions | 2 | 2009 | 143 | 0.060 |
Why?
|
| Bison | 1 | 2006 | 1 | 0.060 |
Why?
|
| Epitopes, T-Lymphocyte | 2 | 2019 | 130 | 0.060 |
Why?
|
| Vaccination | 3 | 2019 | 1017 | 0.060 |
Why?
|
| Endocrine System | 1 | 2006 | 18 | 0.060 |
Why?
|
| Informed Consent | 1 | 2009 | 346 | 0.060 |
Why?
|
| Thymidylate Synthase | 1 | 2006 | 21 | 0.060 |
Why?
|
| Culture | 2 | 2019 | 72 | 0.060 |
Why?
|
| Lunch | 2 | 2018 | 14 | 0.060 |
Why?
|
| Thymus Gland | 2 | 2003 | 100 | 0.060 |
Why?
|
| Family Characteristics | 1 | 2006 | 91 | 0.060 |
Why?
|
| Principal Component Analysis | 1 | 2006 | 156 | 0.060 |
Why?
|
| Environmental Exposure | 1 | 2008 | 236 | 0.060 |
Why?
|
| Genes, Plant | 1 | 2006 | 40 | 0.060 |
Why?
|
| Survival Rate | 2 | 2016 | 2187 | 0.060 |
Why?
|
| Qualitative Research | 1 | 2009 | 664 | 0.060 |
Why?
|
| Peptide YY | 1 | 2005 | 19 | 0.060 |
Why?
|
| Endopeptidases | 1 | 2006 | 114 | 0.060 |
Why?
|
| Maternal Age | 1 | 2006 | 141 | 0.060 |
Why?
|
| Military Personnel | 2 | 2021 | 203 | 0.060 |
Why?
|
| Brain | 2 | 2015 | 3200 | 0.060 |
Why?
|
| Adipose Tissue, Brown | 2 | 2018 | 86 | 0.060 |
Why?
|
| Microsatellite Repeats | 1 | 2006 | 236 | 0.060 |
Why?
|
| World Health Organization | 2 | 2016 | 119 | 0.060 |
Why?
|
| Plant Proteins | 1 | 2006 | 91 | 0.060 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2005 | 29 | 0.060 |
Why?
|
| Software Design | 1 | 2005 | 23 | 0.060 |
Why?
|
| Zambia | 1 | 2025 | 22 | 0.060 |
Why?
|
| Computer Graphics | 1 | 2005 | 38 | 0.060 |
Why?
|
| Database Management Systems | 1 | 2005 | 30 | 0.060 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2009 | 461 | 0.060 |
Why?
|
| Microarray Analysis | 1 | 2006 | 237 | 0.060 |
Why?
|
| CTLA-4 Antigen | 2 | 2019 | 66 | 0.060 |
Why?
|
| Mental Recall | 1 | 2006 | 144 | 0.060 |
Why?
|
| Oxidation-Reduction | 2 | 2016 | 459 | 0.060 |
Why?
|
| Computers | 1 | 2005 | 70 | 0.060 |
Why?
|
| DNA, Complementary | 1 | 2006 | 454 | 0.060 |
Why?
|
| Ephedra sinica | 1 | 2004 | 1 | 0.060 |
Why?
|
| Cola | 1 | 2004 | 1 | 0.060 |
Why?
|
| Salix | 1 | 2004 | 1 | 0.060 |
Why?
|
| Molecular Probe Techniques | 1 | 2005 | 23 | 0.060 |
Why?
|
| Ephedrine | 1 | 2004 | 5 | 0.060 |
Why?
|
| Arabidopsis | 1 | 2006 | 93 | 0.060 |
Why?
|
| Serum | 1 | 2005 | 44 | 0.060 |
Why?
|
| Benzyl Alcohols | 1 | 2004 | 14 | 0.060 |
Why?
|
| Neurodegenerative Diseases | 1 | 2008 | 281 | 0.060 |
Why?
|
| Adipogenesis | 1 | 2005 | 80 | 0.060 |
Why?
|
| Logic | 1 | 2004 | 9 | 0.060 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2006 | 258 | 0.060 |
Why?
|
| Adenovirus Infections, Human | 1 | 2005 | 57 | 0.060 |
Why?
|
| Calorimetry | 2 | 1995 | 64 | 0.060 |
Why?
|
| Melanocytes | 1 | 2024 | 47 | 0.060 |
Why?
|
| Biological Clocks | 1 | 2024 | 29 | 0.060 |
Why?
|
| Dermis | 1 | 2024 | 27 | 0.060 |
Why?
|
| Mathematics | 1 | 2004 | 88 | 0.060 |
Why?
|
| Tobacco Use Disorder | 1 | 2005 | 87 | 0.060 |
Why?
|
| Epidermis | 1 | 2024 | 64 | 0.050 |
Why?
|
| Safety | 2 | 2005 | 217 | 0.050 |
Why?
|
| Neurons | 1 | 2014 | 2017 | 0.050 |
Why?
|
| Actigraphy | 1 | 2024 | 48 | 0.050 |
Why?
|
| Spatial Navigation | 1 | 2024 | 23 | 0.050 |
Why?
|
| Government | 1 | 2024 | 15 | 0.050 |
Why?
|
| Lipase | 1 | 2004 | 98 | 0.050 |
Why?
|
| Workplace | 1 | 2025 | 82 | 0.050 |
Why?
|
| Electronic Health Records | 2 | 2025 | 802 | 0.050 |
Why?
|
| User-Computer Interface | 1 | 2005 | 168 | 0.050 |
Why?
|
| Intention to Treat Analysis | 2 | 2015 | 65 | 0.050 |
Why?
|
| Adenoviridae | 1 | 2006 | 596 | 0.050 |
Why?
|
| Ultraviolet Rays | 1 | 2024 | 202 | 0.050 |
Why?
|
| Potassium Channel Blockers | 1 | 2004 | 84 | 0.050 |
Why?
|
| NFATC Transcription Factors | 1 | 2024 | 38 | 0.050 |
Why?
|
| Chromatography, Liquid | 1 | 2005 | 243 | 0.050 |
Why?
|
| Disease Transmission, Infectious | 1 | 2004 | 86 | 0.050 |
Why?
|
| Uganda | 1 | 2024 | 89 | 0.050 |
Why?
|
| Liver | 3 | 2016 | 1816 | 0.050 |
Why?
|
| RANK Ligand | 1 | 2024 | 54 | 0.050 |
Why?
|
| Hordeum | 1 | 2003 | 5 | 0.050 |
Why?
|
| Osteoclasts | 1 | 2024 | 72 | 0.050 |
Why?
|
| Sequence Alignment | 1 | 2005 | 617 | 0.050 |
Why?
|
| Lactic Acid | 1 | 2024 | 159 | 0.050 |
Why?
|
| Geography | 2 | 2014 | 124 | 0.050 |
Why?
|
| Academic Medical Centers | 1 | 2025 | 332 | 0.050 |
Why?
|
| Mass Spectrometry | 1 | 2005 | 368 | 0.050 |
Why?
|
| Incidence | 3 | 2018 | 3362 | 0.050 |
Why?
|
| Stochastic Processes | 1 | 2003 | 38 | 0.050 |
Why?
|
| Heterotrimeric GTP-Binding Proteins | 1 | 2003 | 32 | 0.050 |
Why?
|
| Ergonomics | 1 | 2023 | 24 | 0.050 |
Why?
|
| Fibroblasts | 2 | 2024 | 879 | 0.050 |
Why?
|
| Disease Progression | 1 | 2010 | 2228 | 0.050 |
Why?
|
| Soybean Proteins | 1 | 2003 | 17 | 0.050 |
Why?
|
| Academies and Institutes | 1 | 2024 | 88 | 0.050 |
Why?
|
| Sickness Impact Profile | 1 | 2003 | 38 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2003 | 94 | 0.050 |
Why?
|
| Self-Assessment | 1 | 2003 | 65 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2012 | 3853 | 0.050 |
Why?
|
| Plethysmography, Impedance | 1 | 2002 | 4 | 0.050 |
Why?
|
| Progestins | 1 | 2023 | 45 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2003 | 150 | 0.050 |
Why?
|
| Adjuvants, Pharmaceutic | 1 | 2022 | 13 | 0.050 |
Why?
|
| Structure-Activity Relationship | 1 | 2004 | 590 | 0.050 |
Why?
|
| Luteinizing Hormone | 1 | 2023 | 136 | 0.050 |
Why?
|
| Videotape Recording | 1 | 2002 | 59 | 0.050 |
Why?
|
| Schizophrenic Psychology | 1 | 2003 | 85 | 0.050 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2023 | 193 | 0.050 |
Why?
|
| Glioblastoma | 1 | 2006 | 374 | 0.050 |
Why?
|
| Genetic Loci | 2 | 2015 | 362 | 0.050 |
Why?
|
| Neoplasm Proteins | 1 | 2006 | 701 | 0.050 |
Why?
|
| Arm | 1 | 2002 | 81 | 0.050 |
Why?
|
| Long-Term Potentiation | 1 | 2022 | 110 | 0.050 |
Why?
|
| Murine hepatitis virus | 1 | 2021 | 3 | 0.050 |
Why?
|
| Health | 1 | 2001 | 39 | 0.040 |
Why?
|
| Thinness | 1 | 2002 | 76 | 0.040 |
Why?
|
| Orexins | 2 | 2013 | 10 | 0.040 |
Why?
|
| Immune System | 1 | 2002 | 97 | 0.040 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2021 | 60 | 0.040 |
Why?
|
| Abdomen | 1 | 2002 | 135 | 0.040 |
Why?
|
| Uncoupling Protein 1 | 2 | 2013 | 32 | 0.040 |
Why?
|
| Cholesterol, HDL | 1 | 2003 | 395 | 0.040 |
Why?
|
| Stress, Physiological | 2 | 2018 | 261 | 0.040 |
Why?
|
| Behavioral Risk Factor Surveillance System | 2 | 2013 | 50 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2004 | 667 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 1 | 2005 | 1294 | 0.040 |
Why?
|
| Emotions | 1 | 2024 | 367 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2006 | 759 | 0.040 |
Why?
|
| Glycoside Hydrolase Inhibitors | 1 | 2020 | 7 | 0.040 |
Why?
|
| Mice, Inbred C3H | 1 | 2020 | 118 | 0.040 |
Why?
|
| Introns | 1 | 2001 | 304 | 0.040 |
Why?
|
| Risk Reduction Behavior | 1 | 2021 | 147 | 0.040 |
Why?
|
| Neuropeptides | 2 | 2013 | 117 | 0.040 |
Why?
|
| Muscle Strength | 1 | 2021 | 86 | 0.040 |
Why?
|
| Receptors, Neuropeptide Y | 2 | 2013 | 8 | 0.040 |
Why?
|
| Social Behavior | 1 | 2002 | 225 | 0.040 |
Why?
|
| Psychotherapy, Group | 1 | 2000 | 59 | 0.040 |
Why?
|
| Administration, Oral | 2 | 2015 | 704 | 0.040 |
Why?
|
| Ion Channels | 2 | 2013 | 207 | 0.040 |
Why?
|
| Viral Proteins | 1 | 2021 | 358 | 0.040 |
Why?
|
| Accelerometry | 1 | 2019 | 64 | 0.040 |
Why?
|
| Lipopolysaccharides | 1 | 2021 | 306 | 0.040 |
Why?
|
| Hypothalamus | 2 | 2013 | 210 | 0.040 |
Why?
|
| Mitochondrial Proteins | 2 | 2013 | 259 | 0.040 |
Why?
|
| Michigan | 1 | 1999 | 50 | 0.040 |
Why?
|
| Immunization Schedule | 1 | 2019 | 107 | 0.040 |
Why?
|
| Antibody Specificity | 1 | 2019 | 201 | 0.040 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 1999 | 70 | 0.040 |
Why?
|
| Isoleucine | 1 | 1999 | 30 | 0.040 |
Why?
|
| Education, Professional | 1 | 2019 | 11 | 0.040 |
Why?
|
| Infant Nutritional Physiological Phenomena | 1 | 2020 | 198 | 0.040 |
Why?
|
| Receptor, Melanocortin, Type 4 | 1 | 1999 | 28 | 0.040 |
Why?
|
| Threonine | 1 | 1999 | 62 | 0.040 |
Why?
|
| Peer Review | 1 | 2019 | 38 | 0.040 |
Why?
|
| Policy | 1 | 2019 | 37 | 0.040 |
Why?
|
| Immunization, Secondary | 1 | 2019 | 113 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2015 | 1292 | 0.040 |
Why?
|
| Arctic Regions | 1 | 2018 | 4 | 0.040 |
Why?
|
| Food Quality | 1 | 2018 | 7 | 0.040 |
Why?
|
| Pain Threshold | 1 | 2018 | 21 | 0.040 |
Why?
|
| Exons | 1 | 2001 | 803 | 0.040 |
Why?
|
| Citrates | 1 | 1998 | 24 | 0.040 |
Why?
|
| Hyperalgesia | 1 | 2018 | 26 | 0.040 |
Why?
|
| Valine | 1 | 1999 | 109 | 0.040 |
Why?
|
| Genetic Association Studies | 2 | 2014 | 856 | 0.040 |
Why?
|
| Mice, Obese | 1 | 2018 | 76 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2021 | 1126 | 0.040 |
Why?
|
| Patient Safety | 1 | 2023 | 437 | 0.040 |
Why?
|
| Methionine | 1 | 1999 | 103 | 0.040 |
Why?
|
| Cell Transplantation | 1 | 2018 | 42 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2021 | 557 | 0.040 |
Why?
|
| Architecture | 1 | 2018 | 2 | 0.040 |
Why?
|
| Corticosterone | 1 | 2018 | 60 | 0.040 |
Why?
|
| Apoptosis | 2 | 2021 | 1904 | 0.040 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2013 | 578 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2020 | 1052 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 1 | 2018 | 258 | 0.030 |
Why?
|
| Adipose Tissue, White | 1 | 2018 | 94 | 0.030 |
Why?
|
| Physical Conditioning, Animal | 1 | 2018 | 85 | 0.030 |
Why?
|
| Cloning, Molecular | 1 | 1999 | 813 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 1999 | 408 | 0.030 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 1 | 2017 | 12 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2018 | 249 | 0.030 |
Why?
|
| Prader-Willi Syndrome | 1 | 1998 | 71 | 0.030 |
Why?
|
| Societies, Scientific | 2 | 2007 | 26 | 0.030 |
Why?
|
| Taste Perception | 1 | 2017 | 5 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2018 | 242 | 0.030 |
Why?
|
| Receptors, Serotonin, 5-HT2 | 1 | 2016 | 2 | 0.030 |
Why?
|
| Life Cycle Stages | 1 | 2016 | 26 | 0.030 |
Why?
|
| Amino Acid Transport Systems | 1 | 2016 | 10 | 0.030 |
Why?
|
| Social Environment | 1 | 1997 | 122 | 0.030 |
Why?
|
| Daphnia | 1 | 2016 | 3 | 0.030 |
Why?
|
| Europe | 2 | 2011 | 373 | 0.030 |
Why?
|
| Tryptophan Hydroxylase | 1 | 2016 | 33 | 0.030 |
Why?
|
| Hydrogen Sulfide | 1 | 2016 | 13 | 0.030 |
Why?
|
| Urban Renewal | 1 | 2016 | 1 | 0.030 |
Why?
|
| Dwarfism | 1 | 2017 | 104 | 0.030 |
Why?
|
| Viral Load | 1 | 2018 | 410 | 0.030 |
Why?
|
| Factor Analysis, Statistical | 1 | 1997 | 235 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2024 | 1975 | 0.030 |
Why?
|
| Africa | 2 | 2011 | 140 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2016 | 138 | 0.030 |
Why?
|
| Body Weight Maintenance | 1 | 2015 | 4 | 0.030 |
Why?
|
| Glycemic Index | 1 | 2015 | 20 | 0.030 |
Why?
|
| Protein Carbonylation | 1 | 2015 | 6 | 0.030 |
Why?
|
| Cell Line | 1 | 2021 | 2730 | 0.030 |
Why?
|
| Denmark | 1 | 2015 | 29 | 0.030 |
Why?
|
| HLA-B27 Antigen | 1 | 2015 | 5 | 0.030 |
Why?
|
| Viral Vaccines | 1 | 2019 | 343 | 0.030 |
Why?
|
| Glutathione Peroxidase | 1 | 2015 | 47 | 0.030 |
Why?
|
| Autonomic Nervous System | 1 | 2016 | 49 | 0.030 |
Why?
|
| Ubiquitin | 1 | 2016 | 142 | 0.030 |
Why?
|
| Islets of Langerhans | 1 | 2016 | 166 | 0.030 |
Why?
|
| Mice, Inbred DBA | 2 | 2006 | 56 | 0.030 |
Why?
|
| Thyroxine | 1 | 1995 | 65 | 0.030 |
Why?
|
| Spatial Learning | 1 | 2015 | 16 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 1999 | 1357 | 0.030 |
Why?
|
| Dentate Gyrus | 1 | 2015 | 39 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2021 | 2453 | 0.030 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2016 | 252 | 0.030 |
Why?
|
| Sodium Chloride, Dietary | 1 | 1995 | 37 | 0.030 |
Why?
|
| Plaque, Amyloid | 1 | 2015 | 70 | 0.030 |
Why?
|
| Superoxide Dismutase | 1 | 2015 | 176 | 0.030 |
Why?
|
| Data Accuracy | 1 | 2014 | 34 | 0.030 |
Why?
|
| Cholelithiasis | 1 | 1994 | 18 | 0.030 |
Why?
|
| Nonlinear Dynamics | 1 | 2014 | 52 | 0.030 |
Why?
|
| Antibodies, Neutralizing | 1 | 2018 | 501 | 0.030 |
Why?
|
| DNA Primers | 1 | 2015 | 637 | 0.030 |
Why?
|
| Alpha-Ketoglutarate-Dependent Dioxygenase FTO | 1 | 2014 | 19 | 0.030 |
Why?
|
| Glutathione | 1 | 2015 | 201 | 0.030 |
Why?
|
| Osteoporosis | 1 | 1995 | 138 | 0.030 |
Why?
|
| Running | 1 | 1994 | 33 | 0.030 |
Why?
|
| Human Body | 1 | 1993 | 2 | 0.030 |
Why?
|
| Microglia | 1 | 2015 | 138 | 0.030 |
Why?
|
| Suppressor of Cytokine Signaling 3 Protein | 1 | 2013 | 12 | 0.030 |
Why?
|
| Lung | 1 | 2021 | 1556 | 0.030 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2013 | 25 | 0.030 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2013 | 40 | 0.030 |
Why?
|
| Receptors, Glucagon | 1 | 2013 | 31 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 1995 | 585 | 0.030 |
Why?
|
| Carbazoles | 1 | 2013 | 29 | 0.030 |
Why?
|
| Agouti-Related Protein | 1 | 2013 | 42 | 0.030 |
Why?
|
| Diabetes, Gestational | 1 | 1995 | 114 | 0.030 |
Why?
|
| Food Services | 1 | 2013 | 42 | 0.030 |
Why?
|
| Morpholines | 1 | 2013 | 67 | 0.030 |
Why?
|
| Immunity, Cellular | 1 | 2014 | 204 | 0.030 |
Why?
|
| Psychometrics | 1 | 1997 | 693 | 0.020 |
Why?
|
| Autophagy | 1 | 2016 | 428 | 0.020 |
Why?
|
| Finite Element Analysis | 1 | 2012 | 36 | 0.020 |
Why?
|
| Philadelphia | 1 | 2012 | 27 | 0.020 |
Why?
|
| Metabolomics | 1 | 2016 | 478 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2018 | 722 | 0.020 |
Why?
|
| Mass Screening | 1 | 1998 | 831 | 0.020 |
Why?
|
| Self Care | 1 | 2014 | 227 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 830 | 0.020 |
Why?
|
| Biomechanical Phenomena | 1 | 2012 | 261 | 0.020 |
Why?
|
| Time | 1 | 2011 | 100 | 0.020 |
Why?
|
| Middle East | 1 | 2011 | 34 | 0.020 |
Why?
|
| Blotting, Southern | 1 | 2011 | 215 | 0.020 |
Why?
|
| Americas | 1 | 2011 | 52 | 0.020 |
Why?
|
| STAT3 Transcription Factor | 1 | 2013 | 232 | 0.020 |
Why?
|
| Arrhythmias, Cardiac | 1 | 1995 | 471 | 0.020 |
Why?
|
| Prognosis | 1 | 2021 | 5010 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2019 | 3873 | 0.020 |
Why?
|
| Asia | 1 | 2011 | 126 | 0.020 |
Why?
|
| Retrospective Studies | 4 | 2014 | 17371 | 0.020 |
Why?
|
| Base Sequence | 1 | 2015 | 2904 | 0.020 |
Why?
|
| DNA Fingerprinting | 1 | 2011 | 109 | 0.020 |
Why?
|
| Bacterial Typing Techniques | 1 | 2011 | 104 | 0.020 |
Why?
|
| Syndrome | 1 | 1993 | 1171 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2024 | 8574 | 0.020 |
Why?
|
| Drosophila Proteins | 1 | 2016 | 768 | 0.020 |
Why?
|
| Geographic Information Systems | 1 | 2010 | 42 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 3780 | 0.020 |
Why?
|
| Gene Library | 1 | 2011 | 213 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2010 | 2064 | 0.020 |
Why?
|
| Leukocytes | 1 | 2011 | 210 | 0.020 |
Why?
|
| Injury Severity Score | 1 | 2011 | 229 | 0.020 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 2011 | 357 | 0.020 |
Why?
|
| Mutation | 1 | 2024 | 6250 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2011 | 299 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2007 | 3062 | 0.020 |
Why?
|
| Fetal Death | 1 | 2010 | 119 | 0.020 |
Why?
|
| Ovulation | 1 | 2010 | 107 | 0.020 |
Why?
|
| DNA, Bacterial | 1 | 2011 | 494 | 0.020 |
Why?
|
| Apolipoprotein A-V | 1 | 2009 | 24 | 0.020 |
Why?
|
| Uncoupling Protein 3 | 1 | 2008 | 7 | 0.020 |
Why?
|
| Breeding | 1 | 2008 | 21 | 0.020 |
Why?
|
| Apolipoproteins A | 1 | 2009 | 54 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2010 | 241 | 0.020 |
Why?
|
| Apolipoprotein C-III | 1 | 2009 | 46 | 0.020 |
Why?
|
| Urban Population | 1 | 2010 | 245 | 0.020 |
Why?
|
| CD36 Antigens | 1 | 2008 | 42 | 0.020 |
Why?
|
| Registries | 1 | 1995 | 1586 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2008 | 378 | 0.020 |
Why?
|
| Body Surface Area | 1 | 2007 | 35 | 0.020 |
Why?
|
| Organ Size | 1 | 2008 | 447 | 0.020 |
Why?
|
| Transcriptome | 1 | 2014 | 1125 | 0.020 |
Why?
|
| Glucose Clamp Technique | 1 | 2007 | 78 | 0.020 |
Why?
|
| Nuclear Receptor Subfamily 4, Group A, Member 1 | 1 | 2007 | 31 | 0.020 |
Why?
|
| Benchmarking | 1 | 2007 | 137 | 0.020 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2006 | 46 | 0.020 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2006 | 66 | 0.020 |
Why?
|
| Receptors, Steroid | 1 | 2007 | 175 | 0.020 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2007 | 199 | 0.020 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 2005 | 23 | 0.020 |
Why?
|
| Biometry | 1 | 2006 | 106 | 0.020 |
Why?
|
| Mice, Inbred ICR | 1 | 2006 | 152 | 0.020 |
Why?
|
| Inbreeding | 1 | 2005 | 7 | 0.010 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2006 | 210 | 0.010 |
Why?
|
| Transgenes | 1 | 2006 | 336 | 0.010 |
Why?
|
| Consumer Product Safety | 1 | 2005 | 32 | 0.010 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2005 | 54 | 0.010 |
Why?
|
| Texas | 1 | 2014 | 3629 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2007 | 748 | 0.010 |
Why?
|
| Equipment Design | 1 | 2007 | 605 | 0.010 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2007 | 326 | 0.010 |
Why?
|
| Health Care Costs | 1 | 2007 | 407 | 0.010 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2004 | 23 | 0.010 |
Why?
|
| Synovial Membrane | 1 | 2004 | 26 | 0.010 |
Why?
|
| Chromosomes | 1 | 2004 | 139 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2006 | 956 | 0.010 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2006 | 520 | 0.010 |
Why?
|
| Disease Management | 1 | 2007 | 565 | 0.010 |
Why?
|
| Chromosomes, Mammalian | 1 | 2003 | 43 | 0.010 |
Why?
|
| Osmolar Concentration | 1 | 2003 | 164 | 0.010 |
Why?
|
| Callitrichinae | 1 | 2002 | 1 | 0.010 |
Why?
|
| C-Peptide | 1 | 2003 | 117 | 0.010 |
Why?
|
| RNA | 1 | 2006 | 549 | 0.010 |
Why?
|
| Cell Division | 1 | 2004 | 744 | 0.010 |
Why?
|
| DNA | 1 | 2008 | 1484 | 0.010 |
Why?
|
| History, 20th Century | 1 | 2003 | 387 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2004 | 691 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2005 | 799 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2004 | 454 | 0.010 |
Why?
|
| Viscera | 1 | 2001 | 55 | 0.010 |
Why?
|
| Cooperative Behavior | 1 | 2002 | 229 | 0.010 |
Why?
|
| Self Disclosure | 1 | 1998 | 26 | 0.010 |
Why?
|
| Electric Impedance | 1 | 1999 | 69 | 0.010 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2003 | 479 | 0.010 |
Why?
|
| Cardiovascular Agents | 1 | 1999 | 87 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2005 | 1098 | 0.010 |
Why?
|
| Psychotropic Drugs | 1 | 1999 | 129 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2007 | 1997 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2000 | 1723 | 0.010 |
Why?
|
| Spinal Diseases | 1 | 1995 | 46 | 0.010 |
Why?
|
| Liver Function Tests | 1 | 1994 | 104 | 0.010 |
Why?
|
| Aspartate Aminotransferases | 1 | 1994 | 83 | 0.010 |
Why?
|
| Body Fluids | 1 | 1994 | 48 | 0.010 |
Why?
|
| Muscles | 1 | 1994 | 252 | 0.010 |
Why?
|
| Alanine Transaminase | 1 | 1994 | 160 | 0.010 |
Why?
|
| Bilirubin | 1 | 1994 | 130 | 0.010 |
Why?
|
| Potassium | 1 | 1994 | 271 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2002 | 1759 | 0.010 |
Why?
|
| Forecasting | 1 | 1993 | 373 | 0.010 |
Why?
|
| Ultrasonography | 1 | 1994 | 988 | 0.000 |
Why?
|